Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities

Inclusion criteria: RET-altered advanced solid tumors. Documented progression of disease following existing therapies.

Sponsor/Collaborator: Helsinn Healthcare SA|ICON Clinical Research

Contact and Locations:
Study contact: Michael Karl
Phone Number: +49 8709 943 761
Email: Michael.Karl@iconplc.com
Locations: https://clinicaltrials.gov/study/NCT04683250#contacts-and-locations

Mechanism of action: TAS0953/HM06 is a structurally distinct RET-specific inhibitor that is effective against RET solvent front (G810) and gatekeeper (V804) mutations.

Phases: Phase 1, Phase 2

NCT Number: NCT04683250

URL: https://clinicaltrials.gov/study/NCT04683250

Status: Recruiting